Dr. Hung Tran | TalkMarkets | Page 2

Dr. Hung Tran

BioSci Capital Partners
Contributor's Links: Dr. Tran Biosci
A strong consulting professional with the Doctor of Medicine and Master of Science from Columbia University. Experienced in biotechnology research analysis with a demonstrated history of working in the healthcare field and the pharmaceuticals industry. Our approach is based on a new investment ...more
Following: 31 Followers: 2992

Articles

Latest Posts
17 to 32 of 102 Posts
<<< 1 2 3 4 ... 7 >>>
Corporate Development: USEC, Inc. To Emerge From Bankruptcy Protection On September 30
Thursday, September 18, 2014 11:51 PM EDT
USU will start trading as LEU; whether USEC ultimately can turn around to become a viable firm remains to be seen, but lower share prices widen the margin of safety.
In this article: USU
Read
Merck Enter Into Licensing Agreement With Sun Pharma For Tildrakizumab
Wednesday, September 17, 2014 1:07 PM EDT
Merck has given exclusive worldwide rights to Sun Pharma to commercialize an agent that is being studied in a stage 3 clinical trial for a certain type of skin condition.
In this article: MRK
Read
Spectrum Pharmaceuticals: Belinostat Injection Received New Patent Coverage
Tuesday, September 16, 2014 10:16 PM EDT
Spectrum Pharmaceutical (SPPI) announced today that it was issued a patent for blinostat, selling under the brand name Beleodaq. The patent extension approval of Spectrum oncology drug is big news for shareholders
In this article: SPPI
Read
Will Fonar Corporation Continue To Post Stellar Earnings
Tuesday, September 16, 2014 2:44 AM EDT
Fonar Corporation (NASDAQ: FONR) recently announced significant earnings increased for fiscal 2014. The stock is a bargain based on valuations. However, investors need to keep tabs on whether the company can continue to add more diagnostic management centers, which is the key to earnings growth.
In this article: FONR
Read
What Investors Should Know About The Greenlight Shining On Conn's, Inc.
Sunday, September 14, 2014 7:44 PM EDT
While the general market seems pessimistic about Conn's prospect, Greenlight Capital Advisors, a fund with an asset under management of $7.1 billion, which returns 13.9 percent compounding gains for the past five years, thinks otherwise.
In this article: CONN
Read
What Investors Should Know About Keryx Pharmaceuticals
Sunday, September 14, 2014 3:42 PM EDT
Since the FDA approved Ferric Citrate, KERX's share price went up 28%. Wall Street analysts, however, are concerned about the drug's warning label of iron overload. But do doctors share that same concern?
In this article: KERX
Read
Why You Should Invest In MannKind Like You Would Invest In A Farm
Sunday, September 14, 2014 10:28 AM EDT
With MannKind share price heading south and the pundits' doomsday forecasting continues, we thought shareholders could appreciate Warren Buffett's 2013 letter to the Berkshire Hathaway shareholders about buying a farm.
In this article: MNKD
Read
Orexigen Received The FDA's Approval For Contrave Yet Questions Remain
Thursday, September 11, 2014 6:33 PM EDT
The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?
In this article: GSK, ARNA, OREX, VVUS
Read
U.S. FDA Approves New Indication For The Use Of XTANDI Capsules For Patients With Metastatic Castration-Resistant Prostate Cancer
Thursday, September 11, 2014 9:31 AM EDT
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC).
In this article: ALPMF, MDVN
Read
Natural Health Trends Corp: Business Fundamentals Unchanged; Company Continues To Execute Its Growth Strategy
Wednesday, September 10, 2014 8:47 PM EDT
Natural Health Trends Corp., which markets premium quality personal care, wellness and “quality of life” products under the NHT Global brand, today commented on the unusual activity related to its common stock.
In this article: NHTC
Read
The Truth Behind The Story Of Inhale Insulin Exubera And Afrezza
Tuesday, September 9, 2014 9:45 PM EDT
MannKind Corporation and Sanofi are poised to launch a new form of fast acting insulin called Afrezza. But will investors be able to forget their disappointment Nektar Therapeutics' insulin inhaler, Exubera, to recognize Afrezza's value?
In this article: PFE, SNY, MNKD, NKTR, ANTB
Read
Spectrum Pharmaceuticals: To Advance The Development Of A Long Acting Granulocyte Colony Stimulating Factor
Tuesday, September 9, 2014 7:34 PM EDT
Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm. Co.
In this article: SPPI
Read
CONN's, Inc.: Classic Market Inefficiency, Solid Earnings Growth, And 50 Percent Upside
Tuesday, September 9, 2014 4:02 PM EDT
Our research suggests that there is at least 50 percent upside of investing in Conn's, Inc. – a retailer operating in a niche market that serves an underserved population.
In this article: CONN
Read
MannKind Corporation: What This Upcoming Tuesday Means For Shareholders
Monday, September 8, 2014 11:07 AM EDT
As MannKind shares have been trading in the low $7 range, investors anxiously await for any news on corporate developments.
In this article: MNKD
Read
Cliffs Natural Resources: A Cyclical Business Where Profit Falls Off The Cliff But Will Rebound In The Future
Monday, September 8, 2014 8:43 AM EDT
Given that Cliffs' profitability depends on the pricing of iron ore, the company will face tough times. Nevertheless, Cliff is an excellent company; the firm will be able to capture significant profits when the industry fundamentals improve.
In this article: CLF
Read
MannKind Captures Lighting In A Bottle And A Rose Was Given To Doctor Mann
Sunday, September 7, 2014 11:14 PM EDT
Supported by Sanofi, MannKind's lead drug Afrezza (a revolutionary medicine to treat diabetes), will soon enter the gigantic global multibillion dollars insulin market. Here's why Mannkind will dominate the diabetes and prediabetes markets...
In this article: SNY, MNKD
Read
17 to 32 of 102 Posts
<<< 1 2 3 4 ... 7 >>>